Genetics  ||| S:0 E:9 ||| NNP
of  ||| S:9 E:12 ||| IN
ankylosing  ||| S:12 E:23 ||| JJ
spondylitis  ||| S:23 E:35 ||| NN
and  ||| S:35 E:39 ||| CC
rheumatoid  ||| S:39 E:50 ||| JJ
arthritis ||| S:50 E:59 ||| NN
:  ||| S:59 E:61 ||| :
where  ||| S:61 E:67 ||| WRB
are  ||| S:67 E:71 ||| VBP
we  ||| S:71 E:74 ||| PRP
at  ||| S:74 E:77 ||| IN
currently ||| S:77 E:86 ||| RB
,  ||| S:86 E:88 ||| ,
and  ||| S:88 E:92 ||| CC
how  ||| S:92 E:96 ||| WRB
do  ||| S:96 E:99 ||| VBP
they  ||| S:99 E:104 ||| PRP
compare ||| S:104 E:111 ||| VBP
?  ||| S:111 E:113 ||| .
Both  ||| S:113 E:118 ||| DT
ankylosing  ||| S:118 E:129 ||| JJ
spondylitis  ||| S:129 E:141 ||| NNS
( ||| S:141 E:142 ||| -LRB-
AS ||| S:142 E:144 ||| NNP
)  ||| S:144 E:146 ||| -RRB-
and  ||| S:146 E:150 ||| CC
rheumatoid  ||| S:150 E:161 ||| JJ
arthritis  ||| S:161 E:171 ||| NN
( ||| S:171 E:172 ||| -LRB-
RA ||| S:172 E:174 ||| NNP
)  ||| S:174 E:176 ||| -RRB-
are  ||| S:176 E:180 ||| VBP
common ||| S:180 E:186 ||| JJ
,  ||| S:186 E:188 ||| ,
highly  ||| S:188 E:195 ||| RB
heritable  ||| S:195 E:205 ||| JJ
conditions ||| S:205 E:215 ||| NNS
,  ||| S:215 E:217 ||| ,
the  ||| S:217 E:221 ||| DT
pathogenesis  ||| S:221 E:234 ||| NN
of  ||| S:234 E:237 ||| IN
which  ||| S:237 E:243 ||| WDT
are  ||| S:243 E:247 ||| VBP
incompletely  ||| S:247 E:260 ||| VBN
understood ||| S:260 E:270 ||| VBN
.  ||| S:270 E:272 ||| .
Gene-mapping  ||| S:272 E:285 ||| JJ
studies  ||| S:285 E:293 ||| NNS
in  ||| S:293 E:296 ||| IN
both  ||| S:296 E:301 ||| DT
conditions  ||| S:301 E:312 ||| NNS
have  ||| S:312 E:317 ||| VBP
over  ||| S:317 E:322 ||| IN
the  ||| S:322 E:326 ||| DT
last  ||| S:326 E:331 ||| JJ
couple  ||| S:331 E:338 ||| NN
of  ||| S:338 E:341 ||| IN
years  ||| S:341 E:347 ||| NNS
made  ||| S:347 E:352 ||| VBD
major  ||| S:352 E:358 ||| JJ
breakthroughs  ||| S:358 E:372 ||| NNS
in  ||| S:372 E:375 ||| IN
identifying  ||| S:375 E:387 ||| VBG
the  ||| S:387 E:391 ||| DT
mechanisms  ||| S:391 E:402 ||| NNS
by  ||| S:402 E:405 ||| IN
which  ||| S:405 E:411 ||| WDT
these  ||| S:411 E:417 ||| DT
diseases  ||| S:417 E:426 ||| NNS
occur ||| S:426 E:431 ||| VBP
.  ||| S:431 E:433 ||| .
Considering  ||| S:433 E:445 ||| VBG
RA ||| S:445 E:447 ||| NNP
,  ||| S:447 E:449 ||| ,
there  ||| S:449 E:455 ||| EX
is  ||| S:455 E:458 ||| VBZ
an  ||| S:458 E:461 ||| DT
over-representation  ||| S:461 E:481 ||| JJ
of  ||| S:481 E:484 ||| IN
genes  ||| S:484 E:490 ||| NNS
involved  ||| S:490 E:499 ||| VBN
in  ||| S:499 E:502 ||| IN
TNF  ||| S:502 E:506 ||| NNP
signalling  ||| S:506 E:517 ||| NN
and  ||| S:517 E:521 ||| CC
the  ||| S:521 E:525 ||| DT
NFKappaB  ||| S:525 E:534 ||| JJ
pathway  ||| S:534 E:542 ||| NN
that  ||| S:542 E:547 ||| WDT
have  ||| S:547 E:552 ||| VBP
been  ||| S:552 E:557 ||| VBN
shown  ||| S:557 E:563 ||| VBN
to  ||| S:563 E:566 ||| TO
influence  ||| S:566 E:576 ||| VB
the  ||| S:576 E:580 ||| DT
disease  ||| S:580 E:588 ||| NN
risk ||| S:588 E:592 ||| NN
.  ||| S:592 E:594 ||| .
There  ||| S:594 E:600 ||| EX
is  ||| S:600 E:603 ||| VBZ
also  ||| S:603 E:608 ||| RB
considerable  ||| S:608 E:621 ||| JJ
sharing  ||| S:621 E:629 ||| NN
of  ||| S:629 E:632 ||| IN
susceptibility  ||| S:632 E:647 ||| JJ
genes  ||| S:647 E:653 ||| NNS
between  ||| S:653 E:661 ||| IN
RA  ||| S:661 E:664 ||| NNP
and  ||| S:664 E:668 ||| CC
other  ||| S:668 E:674 ||| JJ
autoimmune  ||| S:674 E:685 ||| JJ
diseases  ||| S:685 E:694 ||| NNS
such  ||| S:694 E:699 ||| JJ
as  ||| S:699 E:702 ||| IN
systemic  ||| S:702 E:711 ||| JJ
lupus  ||| S:711 E:717 ||| JJ
erythematosus ||| S:717 E:730 ||| NN
,  ||| S:730 E:732 ||| ,
type  ||| S:732 E:737 ||| NN
1  ||| S:737 E:739 ||| CD
diabetes ||| S:739 E:747 ||| NN
,  ||| S:747 E:749 ||| ,
autoimmune  ||| S:749 E:760 ||| JJ
thyroid  ||| S:760 E:768 ||| JJ
disease  ||| S:768 E:776 ||| NN
and  ||| S:776 E:780 ||| CC
celiac  ||| S:780 E:787 ||| JJ
disease ||| S:787 E:794 ||| NN
,  ||| S:794 E:796 ||| ,
with  ||| S:796 E:801 ||| IN
thus  ||| S:801 E:806 ||| RB
far  ||| S:806 E:810 ||| RB
little  ||| S:810 E:817 ||| JJ
overlap  ||| S:817 E:825 ||| NN
with  ||| S:825 E:830 ||| IN
AS ||| S:830 E:832 ||| NNP
.  ||| S:832 E:834 ||| .
In  ||| S:834 E:837 ||| IN
AS ||| S:837 E:839 ||| NNP
,  ||| S:839 E:841 ||| ,
genes  ||| S:841 E:847 ||| NNS
involved  ||| S:847 E:856 ||| VBN
in  ||| S:856 E:859 ||| IN
response  ||| S:859 E:868 ||| NN
to  ||| S:868 E:871 ||| TO
IL12 ||| S:871 E:875 ||| CD
/ ||| S:875 E:876 ||| CD
IL23 ||| S:876 E:880 ||| CD
,  ||| S:880 E:882 ||| ,
and  ||| S:882 E:886 ||| CC
in  ||| S:886 E:889 ||| IN
endoplasmic  ||| S:889 E:901 ||| JJ
reticulum  ||| S:901 E:911 ||| JJ
peptide  ||| S:911 E:919 ||| JJ
presentation ||| S:919 E:931 ||| NN
,  ||| S:931 E:933 ||| ,
have  ||| S:933 E:938 ||| VBP
been  ||| S:938 E:943 ||| VBN
identified ||| S:943 E:953 ||| VBN
,  ||| S:953 E:955 ||| ,
but  ||| S:955 E:959 ||| CC
a  ||| S:959 E:961 ||| DT
full  ||| S:961 E:966 ||| JJ
genomewide  ||| S:966 E:977 ||| JJ
association  ||| S:977 E:989 ||| NN
study  ||| S:989 E:995 ||| NN
has  ||| S:995 E:999 ||| VBZ
not  ||| S:999 E:1003 ||| RB
yet  ||| S:1003 E:1007 ||| RB
been  ||| S:1007 E:1012 ||| VBN
reported ||| S:1012 E:1020 ||| VBN
.  ||| S:1020 E:1022 ||| .
